Seyed Hossein Mosavi

Kidney dysfunction is a clinical disease that disables the kidneys to remove the waste products and uremic toxins from the circulation and may lead to fatal kidney failure. Hemodialysis is advantageous in this circumstance since it prevents the accumulation of waste products in the body and facilitates the removal of uremic toxins. However, hemodialysis cannot entirely remove some uremic toxins, such as urea and creatinine. In this paper, a high-performance fixed-bed column for urea and creatinine removal was offered. As a result, a MOF layer was built on SiO₂, which was then amino-functionalized using APTES. Numerous assays were used to characterize the final adsorbent. The adsorption of urea and creatinine was evaluated in batch and continuous conditions. Thus, it was demonstrated that the adsorption behavior of A(0.2)-IRMOF-1@SiO₂ followed the Langmuir isotherm, and it exhibited the maximum adsorption capacity. The batch experiment determined that urea and creatinine had an adsorption capacity of 1325.73 and 625.00 mg·g^-1, respectively. The adsorption capacity was increased, which was due to the presence of amino groups (APTES) on the MOF surface. The continuous operation was evaluated using the A(0.2)-IRMOF-1@SiO₂ fixed-bed column. Thomas and Nelson's models were examined to achieve a better understanding of the adsorption behaviors. The A(0.2)-IRMOF-1@SiO₂ fixed-bed column successfully removed 92.57% of urea and 80.47% of creatinine. The separation factor for urea in comparison to creatinine was 2.40 in the A(0.2)-IRMOF-1@SiO₂ fixed-bed column.

Cancer is one of the most difficult diseases to treat, threatening the lives of millions of people today. So far, various methods have been used to treat cancer, each having its drawbacks. One of these methods is treatment with anticancer drugs, which unfortunately have severe side effects. One of the causes of these complications is the nonspecific effects of anticancer drugs, which attack normal cells in addition to cancer cells and damage healthy tissues. In this study, we are trying to reduce the side effects and increase the efficacy of the drug by providing smart drug delivery. The metal-organic framework (MOF) was rapidly synthesized using a microwave method and at the nanoscale. The particle size of NMOF-5 was 18-20 nm, and its surface area was 2690 m²·g^-1. A chitosan polymer coating was formed on the nanocarrier after 6-mercaptopurine was introduced. The biocompatible nanocarrier exhibited a high capacity to adsorb the drug. The biocompatible nanocarrier slowly and uniformly released 96.78% of the drug in a simulated solution at pH 5 and 20.52% at pH 7.4. This showed that CS-6-MP-NMOF-5 released the drug smartly and pH-sensitively. The stability of the biocompatible nanocarrier was studied at different pH values and remained stable at pH 5 for up to 48 h. The toxicity study of the MCF-7 cell line at different concentrations for 24 h showed the excellent performance of the biocompatible nanocarrier compared to the free drug in terms of toxicity to breast cancer cells.